Diagnosis: Active Chronic Hepatitis B Infection
This serologic pattern (HBsAg+, anti-HBc+, anti-HBe+) indicates active chronic hepatitis B infection, most likely in the HBeAg-negative chronic hepatitis B phase, and requires immediate HBV DNA quantification and ALT measurement to determine treatment eligibility 1.
Interpretation of Serologic Results
Your patient's reactive markers indicate:
- HBsAg positive: Active HBV infection (not resolved)
- Anti-HBc positive: Confirms HBV exposure and ongoing or past infection
- Anti-HBe positive: Indicates HBeAg-negative phase (either inactive carrier or chronic hepatitis B)
The critical distinction is whether this represents:
- HBeAg-negative chronic hepatitis B (active disease requiring treatment)
- HBeAg-negative chronic HBV infection (inactive carrier state)
Immediate Next Steps
Order these tests immediately to guide management:
- HBV DNA quantification (viral load)
- ALT level
- Liver stiffness measurement (LSM) or assessment of fibrosis stage
- HBeAg status (to confirm negative)
Treatment Decision Algorithm
Based on 2025 EASL guidelines 1:
Treat if ANY of the following:
HBV DNA >2,000 IU/ml AND ALT >ULN (upper limit normal) with or without significant fibrosis → Strong recommendation for treatment 1
Any detectable HBV DNA with cirrhosis → Treat regardless of ALT or viral load 1
Any detectable HBV DNA with advanced fibrosis (LSM >8 kPa or Metavir >F3) → Can treat regardless of ALT 1
HBV DNA <2,000 IU/ml but persistently elevated ALT → Can treat, but exclude other liver diseases first 1
Monitor without treatment if:
- HBV DNA <2,000 IU/ml AND normal ALT AND no significant fibrosis
- This represents inactive carrier state requiring surveillance every 6-12 months
Common Pitfalls to Avoid
Do not assume inactive carrier status without HBV DNA confirmation. Anti-HBe positivity alone does not guarantee low viral replication—approximately 20-30% of anti-HBe positive patients have HBeAg-negative chronic hepatitis B with active viral replication and progressive liver disease 2.
Do not delay HBV DNA testing. The serologic pattern alone cannot distinguish between inactive infection (benign) and active chronic hepatitis requiring treatment (progressive disease risk).
Consider false-positive HBsAg if clinical picture doesn't fit. Confirm with HBV DNA testing and consider neutralization testing if suspicion exists, particularly in hemodialysis patients or those with heterophilic antibodies 1.
Additional Considerations
HBsAg quantification can provide prognostic information: low levels (<1,000 IU/ml) in HBeAg-negative patients suggest inactive carrier state and lower HCC risk 2, 3
Screen household and sexual contacts for HBV and vaccinate if susceptible
Assess for HCC risk factors and initiate surveillance if indicated (cirrhosis, family history, age >40 with ongoing inflammation)